Amneal Operating Margin from 2010 to 2024

AMRX Stock  USD 9.03  0.22  2.38%   
Amneal Pharmaceuticals, Operating Profit Margin yearly trend continues to be fairly stable with very little volatility. Operating Profit Margin is likely to outpace its year average in 2024.
Check Amneal Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amneal Pharmaceuticals,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 154.9 M, Interest Expense of 119.8 M or Selling General Administrative of 281.2 M, as well as many indicators such as Price To Sales Ratio of 0.42, Dividend Yield of 0.096 or PTB Ratio of 56.75. Amneal financial statements analysis is a perfect complement when working with Amneal Pharmaceuticals, Valuation or Volatility modules.
  
Check out the analysis of Amneal Pharmaceuticals, Correlation against competitors.

Latest Amneal Pharmaceuticals,'s Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Amneal Pharmaceuticals, Class over the last few years. It is Amneal Pharmaceuticals,'s Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amneal Pharmaceuticals,'s overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.13 %10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

Amneal Operating Margin Regression Statistics

Arithmetic Mean0.17
Geometric Mean0.14
Coefficient Of Variation73.59
Mean Deviation0.11
Median0.24
Standard Deviation0.13
Sample Variance0.02
Range0.3683
R-Value(0.71)
Mean Square Error0.01
R-Squared0.50
Significance0
Slope(0.02)
Total Sum of Squares0.22

Amneal Operating Margin History

2024 0.14
2023 0.0854
2022 0.0933
2021 0.0999
2020 0.0457
2019 -0.0845
2018 -0.0118

About Amneal Pharmaceuticals, Financial Statements

Amneal Pharmaceuticals, investors use historical fundamental indicators, such as Amneal Pharmaceuticals,'s Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Amneal Pharmaceuticals,. Please read more on our technical analysis and fundamental analysis pages.
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. Amneal Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 7000 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.